

## DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE PRESCRIBING SPECIFICATION 2017-18

### Intentions of the prescribing specification

The prescribing specification is part of the healthcare services contract commissioners (CCGs) has with provider organisations. This document outlines the role and responsibilities of our provider trusts in ensuring a transparent and collaborative approach to the safe and effective management of medicines, seamless care of patients between NHS organisations and ensuring high quality prescribing. The document is updated annually for changes in process and best practice and taken to JAPC (with representatives from both commissioner and provider organisations across Derbyshire) to ensure that its requirements are both fair and reasonable. Once agreed by JAPC, the specification can then be included as part of the contract prescribing requirements from providers for the following contract year.

- Drugs and treatments commissioned by NHS England are not included into this prescribing specification
- Derbyshire Clinical Commissioning Groups (CCGs) require that the pharmaceutical services provided by the Trusts from which they commission services comply with national Service Specifications and Performance Indicators and all relevant national and regional circulars, examples include standards from the Royal Pharmaceutical Society, the NHS constitution, and recommendations by the Derbyshire Joint Area Prescribing Committee.
- The requirements set out in this prescribing specification applies to private providers of healthcare where patients treated privately transfer into the NHS. Patients moving into the NHS setting will be treated the same way as any other NHS patient and GPs will prescribe in line with local policies. Private patients prescribed non-Derbyshire formulary items will be counselled to expect NHS Derbyshire formulary drugs if moving into the NHS.
- Private providers contracted to treat NHS patients are required to follow the commissioning intentions of this specification

The provider trust will ensure that it has internal processes in place in order to meet 100% compliance, but commissioners recognise that there will be acceptable and appropriate exceptions. An exception report will be considered by appropriate D&Ts to ensure that a high level of clinically quality is continually maintained.

No	PERFORMANCE INDICATOR	THRESHOLD	METHOD OF MEASUREMENT	CONSEQUENCE OF BREACH
1.	<p>There will be systems and policies in place to ensure the efficient management of medicines, including:-</p> <ul style="list-style-type: none"> <li>✓ A multidisciplinary Drugs and Therapeutics Committee (MDTC) to include representation from primary care. <ul style="list-style-type: none"> <li>○ Where provider organisations operate without the full functions of a MDTC and adopt formularies and policies from the Joint Area Prescribing Committee, primary care representation on such groups may not be needed. As good practice timely minutes of their meeting will be made available to JAPC.</li> </ul> </li> <li>✓ Systems for formulary management and prescribing audit.</li> <li>✓ A policy for the planned introduction of new drugs.</li> <li>✓ A policy for the use of patients own drugs and their reissue to patients on discharge</li> <li>✓ A policy for the safe and secure handling of medicines</li> <li>✓ Sponsorship policies as agreed by Providers</li> <li>✓ Collaborative relationships with pharma should be covered within the industry policy</li> <li>✓ Management of Conflicts of interests</li> <li>✓ Adequate quality assurance systems</li> <li>✓ A control of infection policy</li> <li>✓ The implementation of NICE recommendations</li> </ul> <p>Hospital Trusts should bring to the attention of the CCG any policies which are not compliant with NICE guidance. All providers should maintain adequate records to demonstrate compliance with NICE guidance.</p>	100% compliance	<p>An annual summary of activities undertaken in respect of this</p> <p>Performance Indicator to be considered by the JAPC</p> <p>Specific audit work</p>	Referred to the Quality Management Group (QMG) for action and to the Contract Management Board (CMB) if necessary
2.	<p>New Treatments and Interventions</p> <p>The Trust will ensure that its clinicians follow due process for the introduction of new drugs or therapies for individuals or groups of patients. This process will ensure:-</p> <ol style="list-style-type: none"> <li>a) Consideration of the drug by the Trust's Drugs and Therapeutics Committee, followed, where appropriate, by</li> <li>b) A paper to the JAPC for consideration or</li> <li>c) A request to the CCG's Non Contract Treatment (Individual Case Review) Panel for consideration.</li> </ol>	100% compliance	Exception reporting by GPs/CCG	Unless specifically agreed by the JAPC/CCG, new treatments and therapies introduced without following due process will not be funded

	Referrals to the Individual Funding Request (IFR) Panel should only be for patients whose circumstances are considered to be exceptional in accordance with the definition contained within the CCG's Policy.			
3.	The Trust will ensure that its employees do not suggest to patients that a non-approved drug or treatment can be obtained from their GP.	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
4.	Primary care and provider trusts will work to the policies, clinical guidelines, shared care agreements, patient group directions and position statements produced and agreed at JAPC	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
5.	<p>Compliance with JAPC Traffic Light Classification for Prescribing i.e.:-</p> <ul style="list-style-type: none"> <li>• <b>RED</b> drugs/appliances/medical devices – Prescribing responsibility lies with a hospital consultant or specialist</li> <li>• <b>AMBER</b> drugs/appliances/medical devices – Initiated and stabilised within a hospital/specialist setting but suitable for shared care with GPs under a shared care arrangement</li> <li>• <b>GREEN</b> drugs/appliances/ medical devices– Regarded as suitable for primary care prescribing</li> <li>• <b>BROWN</b> drugs/appliances/medical devices – not recommended for use or for use in restricted circumstances only. Drugs listed in the BNF are sometimes prescribed in an alternative, unlicensed formulation to meet the individual needs of a patient- these 'specials' are considered to be BROWN drugs, and should only be prescribed on an exceptional basis when a licensed, cost-effective product is not available</li> <li>• <b>BLACK</b> drugs/appliances/medical devices – These are drugs not routinely recommended or commissioned*. These may include for example drugs classified by the BNF as 'less suitable for prescribing' and anything not listed in the BNF e.g. 'herbal medicines'</li> </ul> <p>*unless agreed through the individual funding request route.</p>	<p>100% compliance</p> <p>100% compliance</p> <p>100% compliance</p> <p>100% compliance</p>	<p>Exception reporting by GPs/CCG/D&amp;T</p> <p>JAPC to be informed by DTC minutes</p>	<p>Recharge the Trusts for the cost of drugs inappropriately passed on to GPs to prescribe, where the cost of the drugs would have been covered by national tariff prices or local contracts</p> <p>Provider trusts will be given a reasonable time period to resolve this by escalation to their DTC or equivalent</p> <p>Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required.</p>

	<p>People on treatment with a <b>BLACK</b> drug designation prior to JAPCs decision should be able to continue treatment until their next medication review where their NHS clinician might consider it appropriate to switch or stop treatment.</p> <p>To adhere to the definition of <u>initiation and recommendation</u></p> <p><u>Initiation</u> is when a consultant/specialist issues the first prescription because:  <i>the patient requires assessment before starting treatment and/or short term assessment of the response to the drug is necessary and GPs will only be asked to continue prescribing when the patient is stable or predictably stable</i></p> <p><u>Recommendation</u> is when a consultant/ specialist asks GPs to prescribe the initial and on-going prescriptions, but ensures that;  <i>There is no immediate need for the treatment and is in line with the outpatient policy and the patient's response to treatment is predictable and safe.</i></p> <p>Where inappropriate requests are identified by primary care clinicians, DTCs will undertake a periodic review and act appropriately.</p>			
6.	<p>For all drugs started in a provider care setting the initiating clinician is responsible for the following:</p> <ul style="list-style-type: none"> <li>✓ considering and advising on contraindications, side effects and interactions</li> <li>✓ patient counselling</li> <li>✓ baseline investigations</li> <li>✓ where appropriate the provision of management plans when starting new medicines</li> <li>✓ On-going monitoring e.g. blood test or ECGs and until requesting the primary care clinician takes responsibility for this as per JAPC traffic light classification.</li> </ul>	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
7.	<p>Undertake a periodic review when requested with primary care colleagues of “specials” to ensure appropriate and cost effective use of NHS resources. Specials are individually prepared unlicensed formulations of existing drugs made for a specific patient. They are usually considerably more expensive than standard preparations</p>	No target	Exception reporting by GPs/CCG	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required

<p><b>8.</b></p>	<p>Shared care must always be subject to a proper written shared care protocol. In the transfer of management and prescribing responsibilities to the GP, it is essential that:-</p> <ul style="list-style-type: none"> <li>• Prescribing responsibility will only be transferred when it is agreed by the consultant and the patient's GP that the patient's condition is stable or predictable following a period of initiation and review.</li> <li>• Dissemination of sufficient information to the GP and other carers had occurred;</li> <li>• Prior agreement has been reached between the GP and consultant before clinical responsibility is transferred;</li> <li>• The GP is in a position to monitor treatment and adjust the dose if necessary;</li> <li>• The drug has received approval by the JAPC.</li> <li>• Communication between primary and secondary care clinicians should be facilitated with a copy or link to an up to date shared care agreement</li> </ul> <p>A GP has the right to refuse to enter into a shared care agreement, but to refuse on the grounds of drug cost alone is unacceptable. CCGs must proactively support implementation of agreed shared care protocols to maximise uptake.</p>	<p>100% compliance</p>	<p>Exception reporting by GPs/CCG/D&amp;T.</p>	<p>Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required.</p> <p>Documented reasons for failure of GPs to accept shared care to be escalated to CCG and D&amp;T groups</p>
<p><b>9.</b></p>	<p>Changes in clinical responsibility must be seamless and invisible and the patient or the patient's representative should not be involved in dialogue between clinicians or be required to act as a purveyor of information or policy. Any changes in responsibility transfer must be done at patient level in the patient's best interest and safely.</p>	<p>100% compliance</p>	<p>Exception reporting by GPs/CCG/D&amp;T</p>	<p>Involvement of Medicines Management and Hospital Pharmacists and CCG and Trust Management as required avoiding a reoccurrence.</p>
<p><b>10.</b></p>	<p>Where a hospital clinician recommends that an out-patient goes to their GP for commencement of new treatment, 5 working days will be given for the GP to receive written information prior to the patient attending the practice. Procedures will be in place to communicate this to the patient at the out-patient appointment. Information should be at the required standard as agreed in contractual quality schedules.</p>			

	<p>Urgent drugs i.e. those required within 5 working days will be supplied by the Hospital/specialist and 28 days will be supplied unless a shorter course of treatment is indicated.</p> <p>Mental Health outpatients may receive less than this dependent on clinical need and risk assessment.</p> <p>Medication information is by generic name, except for those agents where it is clinically necessary to indicate the brand prescribed for therapeutic or safety reasons as per JAPC recommendations.</p> <p>Trusts will ensure that whenever possible clinicians recommend a specific drug in accordance with current formularies. The prescribing of “special” formulations should only be considered when suitable alternative proprietary options have been exhausted.</p>	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
11.	<p>In-patients on discharge or transfer shall receive a minimum of 14 days treatment for all drugs and appliances unless otherwise indicated clinically (e.g. short courses or risk assessment). The 14 day treatment can be a reconciliation of medicines supplied by the trust and where appropriate medicines brought in by the patient, reducing unnecessary waste. Wherever possible patients will be encouraged to use their own medicines. A further exception to the 14 days is the supply of oral nutritional supplements whereby the provider will ensure 5-7 days is available.</p> <p>Patients attending for day case surgery will be provided with sufficient dressings/ antibiotics/ analgesia to meet their post-operative needs.</p> <p>On discharge, patients will be provided with clear written instructions outlining their personal drug regimen.</p> <p>Medication information is by generic name, except for those agents where it is clinically necessary to indicate the brand prescribed for therapeutic or safety reasons as per JAPC recommendations.</p> <p>Trusts will ensure that whenever possible clinicians recommend a specific drug in accordance with current formularies. The prescribing of “special” formulations should only be considered when suitable alternative proprietary options have been exhausted.</p>	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required

12.	There must be CCG involvement in any significant developments concerning prescribing, and particularly changes in hospital prescribing practice which will impact on GP prescribing. This involvement may be via the Trust's Drugs and Therapeutic Committee or the JAPC depending on the nature of the change.	100% compliance	Exception reporting by GPs/CCG/D&T	Any significant change will not be supported unless the CCGs are fully engaged in discussions. All parties need to consider National, Regional and local QIPP plans in these developments
13.	<p>Drug choice in the hospital or joint formulary will take into account differentials in the cost of drugs between primary and secondary care and reflect sound cost benefit analysis. Medicines will not be prescribed solely on the basis of advantageous pricing or other financial incentive.</p> <p>To include primary care commissioners in any procurement or rebate process that has the potential to impact on primary care or hospital prescribing budgets. The overall benefit to the health economy will be used as a guide to support provider trusts to compensate loss of income.</p>	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
14.	Where a non-formulary drug is recommended, the consultant will negotiate its supply from within the Trust. GPs should not be asked to prescribe drugs not approved for use in the Trust where the specialist works, unless by specific written agreement with an individual patient's GP. GPs may continue prescribing of concessionary drugs approved through a process of DTC if the exceptionality is agreed by the host commissioning CCG or local guidance of exceptionality	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
15.	If a medication dressing or appliance is not available on GP prescription and initiated by the Trust, it will continue to be supplied by the Trust.	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required
16.	Responsibility for the prescribing of unlicensed drugs or use of drugs off-label will not be transferred to GPs without their prior agreement (exceptions include recognised standards of prescribing practice e.g. paediatrics, dermatology and palliative care).	95% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required

17.	Drugs being used as part of a hospital-initiated clinical trial will be supplied by the hospital.	100% compliance	Exception reporting by GPs/CCG/D&T	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required.
18.	Trusts and CCGs will fully comply with Derbyshire CCG Research Forum recommendations for Funding of Clinical Trials	100% compliance	Exception reporting by GPs/CCG/D&T	CCGs will not pick up post-trial prescribing or other financial implications unless the CCGs have agreed prior to the commencement of the trial to do so.
19.	Clinical staff will be required to provide declarations of conflicts of interest when requesting new drugs / changes to the prescribing formulary; these will be documented in relevant minutes, and are in addition to any declarations made under Standing Financial Instructions. Trusts should demonstrate that sponsorship has in no way affected purchasing decisions and is in accordance with Provider's sponsorship policies.	100% compliance	Details should be included in the annual report to JAPC	Referred to the Quality Management Group (QMG) for action and to the Contract Management Board (CMB) if necessary
20.	The Trust will agree with commissioners the introduction of any new drug, intervention or device, which is excluded from the national tariff, either recommended by NICE or otherwise, as to the appropriateness of its introduction and cost implications of such.	100% compliance	All such discussions to take place at the JAPC and the decision to be ratified by the CCGs.	The introduction of any new therapy without the prior agreement of CCGs will not be funded.
21.	If the Trust has a particular problem with the cost of a drug or treatment not covered by NICE guidance, it will request the specific approval of commissioners for additional funding before commencement of treatment and without raising patient expectation, indicating the benefits of the drug and cost implications.	100% compliance	All such discussions to take place at the JAPC, and the decision to be ratified by the CCGs, or via requests to the NCT (Individual Care Review) panels as appropriate.	In the absence of agreement from the commissioners, the Trust will absorb the costs if it elects to prescribe.
22.	The Trust should provide a medication reconciliation service on admission in accordance with NICE and National Patient Safety Agency guidance issued in December 2007	100% compliance	The availability of the service	
23.	Specific drugs under the QIPP agenda as performance indicators are listed in appendix 1	95% Compliance	Exception reporting by GPs/CCG/D&T	Decisions to be monitored by the JAPC and action taken to resolve any variances.



<b>24.</b>	Decisions reached by the JAPC with provider trusts throughout the year about the appropriate responsibility for the prescribing of pharmaceutical products will be implemented following an approved plan and monitored as agreed.	100% compliance	Exception reporting by GPs/CCG/D&T	Decisions to be monitored by the JAPC and action taken to resolve any variances.
<b>25.</b>	Medication required for planned hospital procedures (for example, EMLA® cream before hospital dialysis, or MRSA eradication) will be prescribed by the hospital/provider and treating clinician.	100% compliance	Exception reporting by GPs/CCG/D&T	Decisions to be monitored by the JAPC and prescribing groups and action taken to resolve any variances.
<b>26.</b>	Trusts will horizon scan and engage with clinicians and medicines management in preparation for the uptake of biosimilars, Details of the uptake is given in the appendix of high cost drugs.	100% compliance	No exceptions	Decisions to be monitored by the JAPC and prescribing groups and action taken to resolve any variances.
<b>27.</b>	To ensure that providers of commissioned services have arrangements in place for the safe management and use of controlled drugs	100% compliance	No exceptions	The CCG nominated lead for controlled drugs will evaluate the concern and escalate to NHSE CD Accountable Officer
<b>28.</b>	MHRA Early Access to Medicines scheme: Provider trusts will have a process within their organisation should they enter into MHRA EAMs schemes. Schemes that have the potential to impact on primary care will be notified to JAPC	100% compliance	No exceptions	Direct contact between Medicines Management and Hospital Pharmacists to avoid recurrence, escalation to QMG if required

## **High Cost Drugs excluded from Tariff commissioned by CCGs**

High Cost Drugs (HCDs) commissioned by specialised services and the NHS England are not included in this specification. JAPC will routinely classify these drugs as 'RED in line with NHSE commissioning intentions' or BLACK as per NICE TA if negative. It will be the responsibility of the provider trust to establish with NHSE how and where it is commissioned. Reference of HCDs in this specification relate solely to those commissioned by CCGs

1. [National tariff](#) Excluded drugs and device costs charged to CCGs will be reflective of actual product cost to providers. CCGs reserve the right to audit provider costs to demonstrate compliance with this term.
2. For High Cost Drugs excluded from tariff that are subject to a re-imburement scheme between the DoH (Department of Health) and drug manufacturer, the provider trust will provide commissioners with monthly updates of new claims by drug name, patient numbers and value.
3. Providers should have in place systems to ensure that medicines excluded from tariff are only charged to the CCG for those uses the CCG have agreed to commission. This includes where there are dual or multiple uses for medicines
4. Concessions for drugs excluded from tariff which have been agreed internally within the provider trust, will not be funded by the CCG. Concession requests which provider trust wish the CCG to pay for should be referred into the commissioning trusts process for individual funding. The provider trust will regularly review concession requests to ensure these are evidence-based and rational – safe, clinical and cost effective - and will seek formulary inclusion if appropriate.
5. For High Cost Drugs excluded from tariff the commissioning trust will only commission in line with NICE (National Institute of Clinical Excellence) Technologies Appraisal Guidance, CCG commissioning intentions or locally produced guidance.
6. For High Cost Drugs excluded from tariff where costs are exceeding planned expenditure or where horizon scanning has identified a significant financial risk to the commissioning CCG, it may decide upon the use of prior approval and/or proformas signed by the patients consultant, in conjunction with the provider trust, to be sent to the CCG as part of the notification; prior approval; or group approval. Data provided to CCGs will not have patient identifiable information.
7. Provider trusts with a monitoring process will provide commissioners with a monthly update of use and expenditure of High Cost Drugs outside tariff, by drug name against predicted spend and budget as set annually by CCGs. For all High Cost Drugs excluded from tariff the provider trust will provide patient level data for on-going quality assurance and validation. This will include the clinical criteria within the NICE technology appraisal or local policy. CCGs will conform to the information governance requirements.
8. For audit of High Cost Drugs excluded from tariff the commissioners require the minimum data set in point 7 to be recorded at patient level to ensure that treatment is in line with NICE or locally agreed guidelines or policies. This will be delivered by appropriate IT software such as Blueteq within a roll-out plan agreed annually with providers.

9. The provider trust, in partnership with the commissioning trust, will undertake sample audits to give assurances of adherence to agreed guidance results of which will be shared with the commissioners where agreed.
10. CCGs can ask provider trust to undertake post-payment verification audits of the use of drugs outside tariffs and/or in non-PbR services.
11. CCGs will reclaim payment (in line with current NHS financial regulations and contract arrangements) of High Cost Drugs excluded from tariff for patients that do not meet commissioning policies.
12. CCGs when challenging treatments with HCDs may ask the provider to clarify their usage it believes falls outside commissioning intentions. The provider will respond within 10 working days with an intention to resolve this issue.
13. CCGs with queries relating to HCDs to the provider trust will receive a response within 10 working days.
14. Any incentive schemes (financial and non-financial) offered to the Provider Trust from the manufacturers shall be disclosed to the Commissioner, whether they are accepted or not before any agreement. This will include offers made by pharmaceutical companies to pay for locally delivered/designed homecare services. Neither the Commissioner nor Provider will be disadvantaged from the acceptance of such schemes. For transparency and fairness any offers to the CCG will be declared to the relevant provider before any decision is made.
15. Commissioners support provider trusts in innovation (for biosimilar uptake see relevant point below) that leads to cost effective prescribing and will always promote collaborative working in a transparent fashion. In cases of expected freed up resources commissioners may enter into a 'benefit share' agreement. Where agreement cannot be reached on share of gains, or proposals offer limited value, the provider will continue to pass through at cost to the CCGs.  
CCG and provider organisations will use NHS England "principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national prices" publication in January 2014 as a framework for CCG commissioned tariff excluded drugs.  
<http://www.england.nhs.uk/wp-content/uploads/2014/01/princ-shar-benefits.pdf>
16. Commercial clinical trials and compassionate funding- Funding arrangements for the period following completion of the trial must be agreed with the commissioners prior to the trial commencing. It should be noted that Derbyshire does not routinely fund medicines that are part of a commercial clinical trial either during the trial period, following the completion of a clinical trial or after withdrawal of compassionate funding by a pharmaceutical company. Ethically, patients participating in a clinical trial must be made aware that there is no guarantee that the medicine will be continued at the end of the trial, irrespective of the results.
17. NICE in all of their positive technology appraisals have a generic statement with the option to continue treatment until they and their clinician consider it appropriate to stop. Patients already treated privately, on a concessionary basis by the provider or through a clinical trial at a point of a positive appraisal relating to their treatment may wish to opt back into NHS. Continuation of treatment under the NHS should not be assumed unless there is evidence the patient meets or would have met the eligibility criteria of NICE. No retrospective funding will be provided.

18. Where drugs and devices outside of commissioned services or commissioning intentions any consequential costs that are incurred will not be funded. This includes the cost associated with the entire treatment.
19. In tariff drugs that prescribed concurrently with PBR excluded drugs are not chargeable as pass through payments. No additional charges above cost will be accepted unless explicitly agreed with CCGs
20. Excluded drugs/devices recommended within a NICE Interventional Procedures Guidance (IPG) and/or guideline will not be routinely funded unless endorsed within a national or locally agreed clinical commissioning policy
21. Budgets for excluded drugs and devices will be set on an annual basis. This will be based on the provider's assessment of need through horizon scanning, and agreed through confirm and challenge meeting by the host commissioning CCG with the provider.
22. High cost treatments and interventions unless specified within contracts, not identified in the annual horizon scan or by exceptional circumstances (e.g. cost neutral or cost saving) will be considered low priority for funding in year. Additional resources may be considered for treatments that are made available at short notice where there is a strong clinical impact on clinical outcomes supported by high quality study(ies)
23. JAPC considers free of charge schemes offered by pharmaceutical companies pre-NICE as a low priority for adoption. In exceptional circumstances patient specific cases may be considered, however, the request must be proposed by the treating clinician and accepted through relevant trust drugs and therapeutics committees which have representation from the CCG using an agreed decision making framework,. The CCG representative should liaise with the clinical effectiveness team for this specialist area.
24. Trusts are expected to plan for the introduction of biosimilar medicines into routine use, in conjunction with clinicians and medicines management when cheaper than the originator. It is essential for the NHS in Derbyshire, both commissioners and providers, that we maximise the financial benefits introducing these agents can realise. To this end we will require a joint improvement programme plan and for all Trusts to use treatments of the lowest acquisition cost to the NHS system, in line with product licenses.

The improvement programme plan should aim\* for all new suitable patients to be initiated on the biosimilar/ generic product within 3 months of them becoming available locally and for existing patients on treatment to have been switched to the biosimilar/ generic product within 15 months of this date. In effect all patients (new and existing) will have moved to the biosimilar no later than 18 months from local availability.

Any resource costs necessary to achieve the switch programme, with prior agreement with the commissioner will be taken from the savings before apportioning the gain share for the biosimilar between provider and commissioner. A standard 50% gain share between provider and commissioner will then be in operation until the end period of the improvement programme plan as described earlier. This accelerated uptake is to reflect the urgency of efficiency savings needed to be realised within the NHS in Derbyshire. After the gain share agreement period, commissioners will only continue to pay at pass through the cost of the cheaper agreed biosimilar\*\*

The Derbyshire JAPC has determined that the starting point for discussing and agreeing a target for uptake will be 100%. This may be revised down with input from local clinicians (those expecting to use the treatment and from different specialties). JAPC will then set a realistic minimum target of achievement for all providers; there will be no variation of thresholds between providers. This process will occur for each biosimilar as they are launched.

\* JAPC may decide to relax time lines in the event for example of another imminent biosimilar launch or the conclusion of a procurement process.

\*\* Switching between biosimilars will be in agreement through JAPC with details of opportunity cost, patient safety and resource to switch as considerations.

25. The collaborative approach for fast uptake of bio-similar is facilitated by 'Derbyshire CCGs principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national tariff prices' document. In the event of disagreement resulting in delay of biosimilar uptake the escalation process would be at director to director level to reflect the financial risk.

#### **Appendix1 – Quality, Innovation, Productivity and Prevention (QIPP)**

The CCGS of Derbyshire and JAPC support the following QIPP areas for implementation to promote cost effective prescribing. These can be accessed through NICE listed as ['key therapeutic topics'](#)

- ✓ Multimorbidity and polypharmacy
- ✓ Psychotropic medicines in people with learning disabilities whose behaviour challenges
- ✓ Medicines optimisation in long-term pain: high risk medicines
- ✓ Safer insulin prescribing
- ✓ Biosimilar medicines
- ✓ Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs)
- ✓ Acute Kidney Injury (AKI): use of medicines in people with or at risk of AKI
- ✓ Lipid modifying drugs
- ✓ Asthma: medicines optimisation priorities
- ✓ Hypnotics
- ✓ Low-dose antipsychotics in people with dementia
- ✓ First-choice antidepressant use in adults with depression or generalised anxiety disorder
- ✓ Antimicrobial stewardship: prescribing antibiotics
- ✓ Type 2 diabetes mellitus
- ✓ Non-steroidal anti-inflammatory drugs
- ✓ Wound care products

## **Appendix 2 – Supporting Medicines Optimisation between Provider Trusts and Commissioners**

Medicines optimisation ensures people obtain the best possible outcomes from their medicines while minimising the risk of harm. Medicines optimisation requires evidence-informed decision making about medicines, involving effective patient engagement and professional collaboration to provide an individualised, person-centred approach to medicines use, within the available resources

Medicines management considers the systems of processes and behaviours determining how medicines are used by patients and the NHS, whereas medicines optimisation focuses on outcomes for patients obtained from their medicines. Medicines management is an important enabler of medicines optimisation and is a term that has been used historically in the NHS for managing people's medicines

NHS Provider Trusts to:

1. Improve medication error reporting and provide evidence quarterly of learning that could be shared across the Derbyshire health community through participation in a local Medicines Safety Officer network to facilitate learning. To share action/mitigation plans with their lead commissioner.
2. Develop mechanisms to support patients to safely use their medicines across secondary and primary care. Provide evidence of collaboration with other Derbyshire Trusts and Commissioners to maximise economies of scale. As a minimum to have an implementation plan in place.
3. Support defined PINCER indicators relevant to the trust:

### **OUTCOME: GI BLEED**

Query 1: Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient aged  $\geq 65$  years

Query 2: Prescription of an oral NSAID, without co-prescription of an ulcer healing drug, to a patient with a history of peptic ulceration

Query 3: Prescription of an antiplatelet drug without co-prescription of an ulcer-healing drug, to a patient with a history of peptic ulceration.

Query 4: Prescription of warfarin or NOAC in combination with an oral NSAID

Query 5: Prescription of warfarin or NOAC and an antiplatelet drug in combination without co-prescription of an ulcer-healing drug

Query 6: Prescription of aspirin in combination with another antiplatelet drug without co-prescription of an ulcer-healing drug

### **OUTCOME: EXACERBATION OF ASTHMA**

Query 1: Prescription of a non-selective beta-blocker to a patient with a history of asthma

Query 2: Prescription of a long-acting beta-2 agonist inhaler (excluding combination products with inhaled corticosteroid) to a patient with asthma who is not also prescribed an inhaled corticosteroid

### **OUTCOME: HEART FAILURE**

Query 1: Prescription of an oral NSAID to a patient with heart failure

### **OUTCOME: STROKE**

Query 1: Prescription of antipsychotics for  $>6$  weeks in a patient aged  $\geq 65$  years with dementia but not psychosis

### **OUTCOME: KIDNEY INJURY**

Query 1: Prescription of an oral NSAID to a patient with eGFR  $< 45$